
OSAKA -- Japanese pharmaceutical company Shionogi has begun a Phase 1 trial of an antiviral pill for COVID-19 patients with light symptoms, joining peers worldwide in seeking a therapy to treat infected people at home.
Drug poised to compete with candidates from Roche-owned Chugai and Merck
OSAKA -- Japanese pharmaceutical company Shionogi has begun a Phase 1 trial of an antiviral pill for COVID-19 patients with light symptoms, joining peers worldwide in seeking a therapy to treat infected people at home.
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.